IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • West, Howard L.; McCleod, Michael; Hussein, Maen; Morabito, Alessandro; Rittmeyer, Achim; Conter, Henry J.; Kopp, Hans-Georg; Daniel, Davey; McCune, Steven; Mekhail, Tarek; Zer, Alona; Reinmuth, Niels; Sadiq, Ahad; Archer, Venice; Lohmann, Tania Ochi; Jessop, Helen; Wang, Lijia; Kowanetz, Marcin; Sandler, Alan; Cappuzzo, Federico

authors

Publication Date

  • July 1, 2019

webpage

published in

category

volume

  • 79

issue

  • 13